The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
Free Articles
Updated: Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Today, we are going to take a comprehensive look at a small-cap biotech company with several near-term catalysts, a strong cash position, and high insider ownership. I feel with all factors considered, this company can see very good price appreciation…
$AVEO calls in one account – screen shot
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Today, we will take a detailed look into a company that has an imminent catalyst, a number of important Phase II and Phase III data releases throughout 2013, and a product pipeline with potential to tap into a $17B market.…
Approaching Biopharma Catalyst Events
Today, I list 4 biopharmas I feel offer strong upside potential in the short and midterm. With these catalysts quickly approaching, we can expect some nice shorter term appreciation under normal market conditions. I feel the 4 stocks I list…
Cleveland BioLabs Offers Medical Countermeasures Against Potential Terrorist Attacks.
Sadly, terrorism is a real threat to the United States homeland as we just saw last week. However, we can take a little solace in the fact that the recent terrorist attack involved crude homemade non-radiological bombs. The fact remains…
